ArticleFrontiers in immunology2021

Clinical Experience of Proteasome Inhibitor Bortezomib Regarding Efficacy and Safety in Severe Systemic Lupus Erythematosus: A Nationwide Study.

Tomas Walhelm et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.